NCT06860984

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Conditions

• Biliary Disease

Interventions

Type	Name	Description
DRUG	Duloxetine	Duloxetine, a non-opioid neuromodulator, has been widely used to manage neuropathic pain. It possesses dual central and peripheral analgesic properties
OTHER	Placebo capsule	Placebo will have the same look and appearance of active comparator

Timeline

• Start date: 2025-03-10
• Primary completion: 2026-06-20
• Completion: 2026-07-10
• First posted: 2025-03-06
• Last updated: 2025-11-18

Locations

1 site across 1 country: Egypt